To determine the association between BK polyomavirus (BKPyV) types 1 and 4 capsid antibody and natalizumab-associated progressive multifocal leukoencephalopathy (PML) in patients with multiple sclerosis (MS), serum samples were obtained from 10 natalizumab-associated PML cases and 130 control MS patients treated with natalizumab, and 82 control MS patients never exposed to natalizumab. In a sex- and age-adjusted regression model, BKPyV serotype 1 antibody levels were significantly higher in natalizumab-treated controls (p = 0.009) compared with cases, and were higher in controls never treated with natalizumab compared with cases, but the difference did not reach statistical significance (p = 0.158). There was no association between BKPyV serotype 4 antibody and PML. We hypothesize that a robust immune response to BKPyV may be protective against the development of PML.
Get full access to this article
View all access options for this article.
References
1.
AntinoriA, AmmassariA, GiancolaML, et al.Epidemiology and prognosis of AIDS-associated progressive multifocal leukoencephalopathy in the HAART era. J Neurovirol, 2001; 7:323–328.
2.
BellizziA, NardisC, AnzivinoE, et al.Human polyomavirus JC reactivation and pathogenetic mechanisms of progressive multifocal leukoencephalopathy and cancer in the era of monoclonal antibody therapies. J Neurovirol, 2012; 18:1–11.
3.
BergerJR, AksamitAJ, CliffordDB, et al.PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology, 2013; 80:1430–1438.
4.
BergerJR, PallL, LanskaD, et al.Progressive multifocal leukoencephalopathy in patients with HIV infection. J Neurovirol, 1998; 4:59–68.
5.
ClausiV, GiannecchiniS, MagnaniE, et al.Markers of JC virus infection in patients with multiple sclerosis under natalizumab therapy. Neurol Neuroimmunol Neuroinflamm, 2015; 2:e58.
6.
EgliA, InfantiL, DumoulinA, et al.Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis, 2009; 199:837–846.
7.
GorelikL, LernerM, BixlerS, et al.Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol, 2010; 68:295–303.
8.
HamiltonRS, GravellM, and MajorEO. Comparison of antibody titers determined by hemagglutination inhibition and enzyme immunoassay for JC virus and BK virus. J Clin Microbiol, 2000; 38:105–109.
9.
HenegarCE, EudyAM, KharatV, et al.Progressive multifocal leukoencephalopathy in patients with systemic lupus erythematosus: a systematic literature review. Lupus, 2016; 25:617–626.
10.
KnowlesWA, PipkinP, AndrewsN, et al.Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol, 2003; 71:115–123.
11.
KrymskayaL, SharmaMC, MartinezJ, et al.Cross-reactivity of T lymphocytes recognizing a human cytotoxic T-lymphocyte epitope within BK and JC virus VP1 polypeptides. J Virol, 2005; 79:11170–11178.
12.
MelisM, BiagiC, SmabrekkeL, NoninoF, et al.Drug-induced progressive multifocal leukoencephalopathy: a comprehensive analysis of the WHO adverse drug reaction database. CNS Drugs, 2015; 29:879–891.
13.
NishimotoY, ZhengHY, ZhongS, et al.An Asian origin for subtype IV BK virus based on phylogenetic analysis. J Mol Evol, 2007; 65:103–111.
14.
PlavinaT, SubramanyamM, BloomgrenG, et al.Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol, 2014; 76:802–812.
15.
RandhawaPS, GuptaG, VatsA, et al.Immunoglobulin G, A, and M responses to BK virus in renal transplantation. Clin Vaccine Immunol, 2006; 13:1057–1063.
16.
RossiF, LiX, JacobsonL, LevineAJ, et al.BK virus capsid antibodies are associated with protection against subsequent development of PML in HIV-infected patients. Virology, 2015; 485:467–472.
17.
RossiF, NewsomeSD, and ViscidiR. Molecular diagnostic tests to predict the risk of progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis patients. Mol Cell Probes, 2015; 29:54–62.
18.
SchwabN, Schneider-HohendorfT, PignoletB, et al.Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values. Neurol Neuroimmunol Neuroinflamm, 2016; 3:e195.
19.
TurC, and MontalbanX. Natalizumab: risk stratification of individual patients with multiple sclerosis. CNS Drugs, 2014; 28:641–648.
20.
ViscidiRP, and ClaymanB. Serological cross reactivity between polyomavirus capsids. Adv Exp Med Biol, 2006; 577:73–84.
21.
ViscidiRP, RollisonDE, SondakVK, et al.Age-specific seroprevalence of Merkel cell polyomavirus, BK virus, and JC virus. Clin Vaccine Immunol, 2011; 18:1737–1743.
22.
ViscidiRP, RollisonDE, ViscidiE, et al.Serological cross-reactivities between antibodies to simian virus 40, BK virus, and JC virus assessed by virus-like-particle-based enzyme immunoassays. Clin Diagn Lab Immunol, 2003; 10:278–285.
